Tuesday, September 22, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Regulatoryorforgliproneli-lillyfdaobesity

FDA approves Eli Lilly's oral GLP-1 orforglipron for obesity

Orforglipron is the first small-molecule, once-daily GLP-1 receptor agonist pill cleared for weight management, giving prescribers a non-injectable incretin option.

DO
By Daniel Okafor · Regulatory Correspondent
Apr 1 03:00 ETSource: The American Journal of Managed Care

The wire

  1. 01The FDA approved Eli Lilly's oral GLP-1 orforglipron for obesity, according to The American Journal of Managed Care.
  2. 02A daily tablet avoids the cold-chain, needle and supply constraints that have shaped injectable incretin dispensing and compounding demand.
  3. 03Pricing, payer coverage and launch volumes will determine real-world access; detailed label terms and rollout timing were not specified in the report.

From the source

FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity

Read at ajmc.com
Source URL https://www.ajmc.com/view/fda-approves-lilly-s-oral-glp-1-orforglipron-for-obesity